Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 127,885 shares of the company's stock, valued at approximately $1,368,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.64% of Keros Therapeutics at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Keros Therapeutics in the 1st quarter worth about $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Keros Therapeutics by 15.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company's stock valued at $227,000 after acquiring an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company's stock valued at $7,547,000 after acquiring an additional 205,022 shares in the last quarter. Creative Planning boosted its holdings in shares of Keros Therapeutics by 40.2% in the second quarter. Creative Planning now owns 24,226 shares of the company's stock valued at $323,000 after purchasing an additional 6,948 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Keros Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 51,815 shares of the company's stock valued at $692,000 after purchasing an additional 7,146 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other news, Director Julius Knowles sold 2,625 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 10,958 shares in the company, valued at approximately $117,579.34. This represents a 19.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nima Farzan sold 2,625 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 9,767 shares of the company's stock, valued at approximately $104,799.91. This represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,768 shares of company stock valued at $144,979 over the last three months. Company insiders own 12.60% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have recently commented on KROS shares. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Wells Fargo & Company lowered their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research note on Tuesday, August 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Zacks Research raised shares of Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday. Finally, Wall Street Zen upgraded shares of Keros Therapeutics from a "strong sell" rating to a "sell" rating in a report on Monday, August 24th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $20.50.
Read Our Latest Stock Report on KROS
Keros Therapeutics Stock Performance
NASDAQ:KROS opened at $11.03 on Friday. The company's 50-day simple moving average is $10.78 and its 200-day simple moving average is $11.61. Keros Therapeutics, Inc. has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The stock has a market capitalization of $218.72 million, a P/E ratio of -2.98 and a beta of 0.99.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, research analysts forecast that Keros Therapeutics, Inc. will post -5.27 EPS for the current year.
Keros Therapeutics Profile
(
Free Report)
Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
